Here, we evaluated the therapeutic potential of antibodies (Abs) focusing on cholinergic receptor nicotinic beta 2 subunit (CHRNB2) in gastric cancer. To examine the results of these Abs on malignant phenotypes in vitro and in mouse xenograft fashions, we generated gene knockouts by way of genome enhancing, carried out RNA interference-mediated knockdown of gene expression, and ectopically expressed CHRNB2 in gastric cancer cells. The results of anti-CHRNB2 Abs on the proliferation of cancer cells had been evaluated each in vitro and in vivo. We decided the results of Chrnb2 deficiency on mice and the medical significance of CHRNB2 expression in gastric cancer medical specimens.
Knockdown of CHRNB2 attenuated gastric cancer cell proliferation, whereas compelled overexpression of CHRNB2 elevated cell proliferation. Knockout of CHRNB2 considerably influenced cell survival and capabilities related with metastasis. The results of polyclonal Abs focusing on the C- and N-termini of CHRNB2 guided the improvement of anti-CHRNB2 monoclonal Abs that inhibited the development of gastric cancer cells in vitro and in vivo. Pathway evaluation revealed that CHRNB2 interfered with signaling by way of the PI3K-AKT and JAK-STAT pathways. Chrnb2-deficient mice exhibited regular replica, organ capabilities, and motor capabilities. CHRNB2 regulates a number of oncological phenotypes related with metastasis, and blockade of CHRNB2 expression utilizing particular Abs exhibits promise for controlling metastasis in gastric cancer.
About 25% of sufferers with IgA nephropathy (IgAN) progress to stage 5 persistent kidney illness (CKD) after years of evolution. Various instruments have been developed in recent times designed to foretell which of the sufferers will had poorer outcomes. The worth of circulating galactosyl-deficient IgA1 (Gd-IgA1) has been associated to a worse evolution of IgAN in a number of research. There are additionally some publications that relate greater APRIL values with a worse evolution. Recently, a new technique has been developed that enables measuring the worth of circulating Gd-IgA1 in a less complicated manner than these beforehand obtainable. The goal of this research is to investigate the affect of circulating Gd-IgA1, measured by this technique, on the development of IgAN.
Monoclonal Antibody Targeting the CD154 Cleavage Site Inhibits CD40-Dependent and -Independent Cleavage of CD154 from the Cell Surface
In addition to the membrane-bound molecule, soluble CD154 (sCD154) can also be detected at excessive ranges in the medium of activated T cells and platelets and in the serum of sufferers affected by completely different inflammatory ailments. This sCD154 is the consequence of cleavage of the full-length molecule between the glutamic acid residue at place 112 (E112) and methionine at place 113 (M113) and will be derived from the intracellular milieu and from cleavage of cell floor molecules. We have just lately reported that substitution of each E112 and M113 by alanine inhibits intracellular and CD40-induced membrane cleavage of CD154 and procures to CD154 an elevated organic operate as in contrast with cleavable CD154.
Thus, on this research, and in the intention of growing instruments inhibiting cleavage of CD154 from the cell floor, we generated a panel of anti-human CD154 mAbs. One of the derived mAbs that didn’t alter the binding of sCD154 to CD40, named on this research Clone eight mAb, completely misplaced its binding exercise in opposition to cells expressing CD154 mutated at its E112 and M113 residues. Treatment with Clone eight mAb was proven to fully abolish CD40-dependent and -independent cleavage of CD154 from the cell floor. Our research is highlighting the improvement and characterization of an modern therapeutic device succesful of inhibiting the launch/cleavage of CD154 from cells and thus sustaining its availability on the cell floor and the excessive in all probability of growing its efficiency as an activator of CD40-induced responses.
In this quasi-experimental pre-/postimplementation research, we estimated the effectiveness of MAb remedy inside 7 days of symptom onset in high-risk ambulatory adults with COVID-19. The main consequence was a composite of emergency division visits or hospitalizations inside 14 days of optimistic check. Secondary outcomes included adversarial occasions and 14-day mortality. The common remedy impact in the handled for MAb remedy was estimated utilizing inverse chance of remedy weighting and the affect of MAb implementation utilizing propensity-weighted interrupted time sequence evaluation.
Electrostatic Spray Drying for Monoclonal Antibody Formulation
This research explored the feasibility of electrostatic spray drying for producing a monoclonal antibody (mAb) powder formulation at decrease drying temperatures than typical spray drying and its impact on protein stability. A mAb formulation was dried by both typical spray drying or electrostatic spray drying with cost (ESD). The protein powders had been then characterised utilizing solid-state Fourier remodel infrared spectroscopy (ssFTIR), differential scanning calorimetry (DSC), dimension exclusion chromatography (SEC), and solid-state hydrogen/deuterium alternate with mass spectrometry (ssHDX-MS).
Particle characterizations reminiscent of BET floor space, particle dimension distribution, and particle morphology had been additionally carried out. Conventional spray drying of the mAb formulation at the inlet temperature of 70°C didn’t generate dry powders as a consequence of poor drying effectivity; electrostatic spray drying at the similar temperature at 5kV enabled the formation of powder formulation with passable moisture contents. Deconvoluted peak areas of deuterated samples from the ssHDX-MS research confirmed a good correlation with the loss of the monomeric peak space measured by dimension exclusion chromatography in the 90-day accelerated stability research carried out at 40°C.
 (Fab 2) (Alexa Fluor 594)) Donkey anti Goat IgG (H + L) (Fab 2) (Alexa Fluor 594) |
|
43R-ID012AF |
Fitzgerald |
300 ug |
EUR 410 |
|
Description: Donkey anti Goat IgG (H + L) secondary antibody (Fab'2) (Alexa Fluor 594) |
 Alexa Fluor 647–conjugated) Goat Anti-Mouse IgG(H+L) Alexa Fluor 647–conjugated |
|
S0014 |
Affbiotech |
200ul |
EUR 304 |
 Alexa Fluor 488–conjugated) Goat Anti-Mouse IgG(H+L) Alexa Fluor 488–conjugated |
|
S0017 |
Affbiotech |
200ul |
EUR 304 |
 (Alexa Fluor 594)) Donkey anti Rat IgG (H + L) (Alexa Fluor 594) |
|
43R-ID022AF |
Fitzgerald |
500 ug |
EUR 364 |
|
Description: Donkey anti Rat IgG (H + L) secondary antibody (Alexa Fluor 594) |
|
Donkey anti Rat IgG (H + L) (Alexa Fluor 594) |
|
43R-ID047AF |
Fitzgerald |
500 ug |
EUR 462 |
|
Description: Donkey anti Rat IgG (H + L) secondary antibody (Alexa Fluor 594) |
 Alexa Fluor 647–conjugated) Goat Anti-Rabbit IgG(H+L) Alexa Fluor 647–conjugated |
|
S0013 |
Affbiotech |
200ul |
EUR 304 |
 Alexa Fluor 488–conjugated) Goat Anti-Rabbit IgG(H+L) Alexa Fluor 488–conjugated |
|
S0018 |
Affbiotech |
200ul |
EUR 304 |
 (Alexa Fluor 647)) Donkey anti Goat IgG (H + L) (Alexa Fluor 647) |
|
43R-ID028AF |
Fitzgerald |
500 ug |
EUR 430 |
|
Description: Donkey anti Goat IgG (H + L) secondary antibody (Alexa Fluor 647) |
) Goat anti Mouse IgG1 (Alexa Fluor 488) |
|
43R-1649 |
Fitzgerald |
500 ug |
EUR 570 |
|
Description: Goat anti Mouse IgG1 secondary antibody (Alexa Fluor 488) |
-Alexa 594 Fluor conjugate (adsorbed with human IgG)) Rabbit Anti-Rat IgG (H+L)-Alexa 594 Fluor conjugate (adsorbed with human IgG) |
|
50337 |
Alpha Diagnostics |
0.5 ml |
EUR 225 |
 (Alexa Fluor 594)) Donkey anti Chicken IgY (H + L) (Alexa Fluor 594) |
|
43R-ID056AF |
Fitzgerald |
500 ug |
EUR 343 |
|
Description: Donkey anti Chicken IgY secondary antibody (H + L) (Alexa Fluor 594) |
 (Alexa Fluor 594)) Rabbit anti Chicken IgY (H + L) (Alexa Fluor 594) |
|
43R-IR016AF |
Fitzgerald |
1 mg |
EUR 281 |
|
Description: Rabbit anti Chicken IgY (H + L) secondary antibody (Alexa Fluor 594) |
, Alexa Fluor® 488 Conjugated) Donkey Anti-Rabbit IgG (H+L), Alexa Fluor® 488 Conjugated |
|
Ab8032-001 |
GenDepot |
0.5mg |
EUR 435 |
 AF594 Phalloidin [equivalent to Alexa Fluor® 594 phalloidin] |
|
23158 |
AAT Bioquest |
300 Tests |
EUR 306 |
- R-phrase: R23, R24, R25
- H-Phrase: H301, H311, H331
- Symbol for dangerous compounds: T
- UNSPEC Code: 12352200
|
 AF594-streptavidin conjugate [Streptavidin, Alexa Fluor™ 594 Conjugate] |
|
16892 |
AAT Bioquest |
1 mg |
EUR 176 |
- R-phrase: R20, R21, R22
- H-Phrase: H303, H313, H333
- Symbol for dangerous compounds: Xn
- UNSPEC Code: 12171501
|
 Anti-RPSA Alexa Fluor® 488 |
|
A4-829-C100 |
ExBio |
0.1 mg |
EUR 310 |
) Anti-CD40 antibody (Alexa-fluor 488) |
|
STJ170000 |
St John's Laboratory |
100 µg |
EUR 393 |
|
Description: CD40 (48 to 50 kDa) is a transmembrane glycoprotein mainly expressed on the surface of B cells and also expressed on monocytes, dendritic cells, and thymic epithelium. CD40 is a member of the tumor necrosis factor (TNF) receptor superfamily, which includes the low affinity nerve growth factor (NGF) receptor and CD95/Fas. CD40 is the receptor for CD40 ligand. CD40L (CD40L, CD154, gp39, and TRAM) belongs to the TNF gene family and is expressed more widely than CD40, predominantly on activated CD4+ T cells. Following interaction with CD40 ligand, CD40 mediates a number of major immunoregulatory functions, central to the control of thymus dependent humoral immunity and may be critical in the development of cell mediated immune responses. Other biological actions include B cell homotypic adhesion, proliferation, immunoglobulin isotype switch, and secretion. Activation of CD40 has also been shown to inhibit the growth of certain B cell lymphomas and to induce the death of transformed cells of mesenchymal or epithelial origin |
) Anti-LAMP3 antibody (Alexa-fluor 488) |
|
STJ170004 |
St John's Laboratory |
100 µg |
EUR 393 |
|
Description: The dendritic cell lysosomal-associated membrane protein (DC-LAMP)/CD208 is a type I integral transmembrane glycoprotein mostly homologous to CD68, of about 45 kDa in mouse and 90 kDa in human (glycosylation), with a bipartite C-terminal structure divided by a serine/proline rich region, a transmembrane domain and a conserved tyrosine-based lysosomal targeting motif in its cytoplasmic tail. Initially cloned as a specific marker of human mature dendritic cells (DCs), DC-LAMP has been subsequently shown to be expressed in alveolar type II pneumocytes. In both cell types, the molecule is found in the limiting membrane of intracellular multi-lamellar bodies, known as MIIC (MHC class II compartments) in human mature DCs and as lung surfactant-containing lamellar bodies in type II pneumocytes. In the latter cell type, DC-LAMP expression is also detected at the cell surface. |
) Anti-LAMP3 antibody (Alexa-fluor 546) |
|
STJ170005 |
St John's Laboratory |
100 µg |
EUR 393 |
|
Description: The dendritic cell lysosomal-associated membrane protein (DC-LAMP)/CD208 is a type I integral transmembrane glycoprotein mostly homologous to CD68, of about 45 kDa in mouse and 90 kDa in human (glycosylation), with a bipartite C-terminal structure divided by a serine/proline rich region, a transmembrane domain and a conserved tyrosine-based lysosomal targeting motif in its cytoplasmic tail. Initially cloned as a specific marker of human mature dendritic cells (DCs), DC-LAMP has been subsequently shown to be expressed in alveolar type II pneumocytes. In both cell types, the molecule is found in the limiting membrane of intracellular multi-lamellar bodies, known as MIIC (MHC class II compartments) in human mature DCs and as lung surfactant-containing lamellar bodies in type II pneumocytes. In the latter cell type, DC-LAMP expression is also detected at the cell surface. |
) Anti-LAMP3 antibody (Alexa-fluor 647) |
|
STJ170006 |
St John's Laboratory |
100 µg |
EUR 393 |
|
Description: The dendritic cell lysosomal-associated membrane protein (DC-LAMP)/CD208 is a type I integral transmembrane glycoprotein mostly homologous to CD68, of about 45 kDa in mouse and 90 kDa in human (glycosylation), with a bipartite C-terminal structure divided by a serine/proline rich region, a transmembrane domain and a conserved tyrosine-based lysosomal targeting motif in its cytoplasmic tail. Initially cloned as a specific marker of human mature dendritic cells (DCs), DC-LAMP has been subsequently shown to be expressed in alveolar type II pneumocytes. In both cell types, the molecule is found in the limiting membrane of intracellular multi-lamellar bodies, known as MIIC (MHC class II compartments) in human mature DCs and as lung surfactant-containing lamellar bodies in type II pneumocytes. In the latter cell type, DC-LAMP expression is also detected at the cell surface. |
) Anti-IL3RA antibody (Alexa-fluor 488) |
|
STJ170009 |
St John's Laboratory |
100 µg |
EUR 393 |
|
Description: IL3 exerts its biologic activity through its interaction with a cell surface receptor that consists of two subunits. The a subunit (CD123) specifically binds IL3, whereas the ß subunit is required for signaling and is common to the GMCSFR and IL5-R. 107D2.08 and 106C2.02 mAbs were obtained after mouse immunization with sorted human tonsillar PDC. Both clones strongly stain PDCs and basophils, weakly stain monocytes, CD34+ derived DCs and CD11c+ DC, while no staining is observed on T, B, NK cells as well as on mono-derived DCs. Staining with 107D2.08 and 106C2.02 mAbs are maintained on sorted PDC cultured in the presence of IL3 and CD40L, but lost when IL3 alone is added to the culture. The recognition of the IL3Ra chain by 107D2.08 and 106C2.02 was confirmed by transfection studies. 107D2.08 appeared to be the most appropriate clone for in situ studies. 107D2.08 allowed the first observation of IL3Ra+ cells in breast tumor microenvironment |
) Anti-IL3RA antibody (Alexa-fluor 546) |
|
STJ170010 |
St John's Laboratory |
100 µg |
EUR 393 |
|
Description: IL3 exerts its biologic activity through its interaction with a cell surface receptor that consists of two subunits. The a subunit (CD123) specifically binds IL3, whereas the ß subunit is required for signaling and is common to the GMCSFR and IL5-R. 107D2.08 and 106C2.02 mAbs were obtained after mouse immunization with sorted human tonsillar PDC. Both clones strongly stain PDCs and basophils, weakly stain monocytes, CD34+ derived DCs and CD11c+ DC, while no staining is observed on T, B, NK cells as well as on mono-derived DCs. Staining with 107D2.08 and 106C2.02 mAbs are maintained on sorted PDC cultured in the presence of IL3 and CD40L, but lost when IL3 alone is added to the culture. The recognition of the IL3Ra chain by 107D2.08 and 106C2.02 was confirmed by transfection studies. 107D2.08 appeared to be the most appropriate clone for in situ studies. 107D2.08 allowed the first observation of IL3Ra+ cells in breast tumor microenvironment |
) Anti-IL3RA antibody (Alexa-fluor 647) |
|
STJ170011 |
St John's Laboratory |
100 µg |
EUR 393 |
|
Description: IL3 exerts its biologic activity through its interaction with a cell surface receptor that consists of two subunits. The a subunit (CD123) specifically binds IL3, whereas the ß subunit is required for signaling and is common to the GMCSFR and IL5-R. 107D2.08 and 106C2.02 mAbs were obtained after mouse immunization with sorted human tonsillar PDC. Both clones strongly stain PDCs and basophils, weakly stain monocytes, CD34+ derived DCs and CD11c+ DC, while no staining is observed on T, B, NK cells as well as on mono-derived DCs. Staining with 107D2.08 and 106C2.02 mAbs are maintained on sorted PDC cultured in the presence of IL3 and CD40L, but lost when IL3 alone is added to the culture. The recognition of the IL3Ra chain by 107D2.08 and 106C2.02 was confirmed by transfection studies. 107D2.08 appeared to be the most appropriate clone for in situ studies. 107D2.08 allowed the first observation of IL3Ra+ cells in breast tumor microenvironment |
) Anti-CD207 antibody (Alexa-fluor 488) |
|
STJ170014 |
St John's Laboratory |
100 µg |
EUR 393 |
|
Description: Langerin/CD207 is a transmembrane C-type lectin receptor (CLR) of epidermal and mucosal Langerhans cells (LCs) that induces Birbeck's granule formation. Langerin features a single carbohydrate recognition domain (CRD) with mannose-type specificity in its extracellular portion. Langerin is unique among the CLRs in that it contains an intracellular domain with a proline-rich motif. Langerin expression has not been reported outside the DC system. (Valladeau J et al, 1999, Eur.J.Immunol., 29:2695-2704; Valladeau J et al, 2000 Immunity, 12 : 71-81; Kashihara M et al, 1986, J.Invest.Derm., 87 :602-607 Ito T et al, 1999, J.Immunol., 163 :1409-1419 ;Saeland S & Valladeau J, CD207 (Langerin) Workshop reports 2002, Leukocyte-Typing VII, White Cell Diff Antigens, D. Mason et al, Eds, Oxford University Press:306-307) |
) Anti-CD207 antibody (Alexa-fluor 546) |
|
STJ170015 |
St John's Laboratory |
100 µg |
EUR 393 |
|
Description: Langerin/CD207 is a transmembrane C-type lectin receptor (CLR) of epidermal and mucosal Langerhans cells (LCs) that induces Birbeck's granule formation. Langerin features a single carbohydrate recognition domain (CRD) with mannose-type specificity in its extracellular portion. Langerin is unique among the CLRs in that it contains an intracellular domain with a proline-rich motif. Langerin expression has not been reported outside the DC system. (Valladeau J et al, 1999, Eur.J.Immunol., 29:2695-2704; Valladeau J et al, 2000 Immunity, 12 : 71-81; Kashihara M et al, 1986, J.Invest.Derm., 87 :602-607 Ito T et al, 1999, J.Immunol., 163 :1409-1419 ;Saeland S & Valladeau J, CD207 (Langerin) Workshop reports 2002, Leukocyte-Typing VII, White Cell Diff Antigens, D. Mason et al, Eds, Oxford University Press:306-307) |
) Anti-CD207 antibody (Alexa-fluor 647) |
|
STJ170016 |
St John's Laboratory |
100 µg |
EUR 393 |
|
Description: Langerin/CD207 is a transmembrane C-type lectin receptor (CLR) of epidermal and mucosal Langerhans cells (LCs) that induces Birbeck's granule formation. Langerin features a single carbohydrate recognition domain (CRD) with mannose-type specificity in its extracellular portion. Langerin is unique among the CLRs in that it contains an intracellular domain with a proline-rich motif. Langerin expression has not been reported outside the DC system. (Valladeau J et al, 1999, Eur.J.Immunol., 29:2695-2704; Valladeau J et al, 2000 Immunity, 12 : 71-81; Kashihara M et al, 1986, J.Invest.Derm., 87 :602-607 Ito T et al, 1999, J.Immunol., 163 :1409-1419 ;Saeland S & Valladeau J, CD207 (Langerin) Workshop reports 2002, Leukocyte-Typing VII, White Cell Diff Antigens, D. Mason et al, Eds, Oxford University Press:306-307) |
) Anti-IL7R antibody (Alexa-fluor 488) |
|
STJ170020 |
St John's Laboratory |
100 µg |
EUR 393 |
|
Description: The IL7-R consists of 2 chains, IL-7R known as CD127 and common cytokine receptor chain known as CD132. A 75 to 80kDa human IL-7 receptor has been cloned that belongs to hematopoietic cytokinereceptor super family. R34-34, raised against human leukemic pre-B cells, recognized a molecule expressed on normal B cell precursors but not on mature B cells. This antibody specifically reverted IL-7 mediated growth inhibition of leukemic BCP (normal B cells precursors) and mature T cells. IL-7R expression is dramatically influenced by cytokines and antigens. This IL-7R displays both high and low affinity for its ligand (IL-7). Inhibitory and proliferative effects of IL-7 can be mediated through the same receptor on various lineages. CD4+ memory T cells express high level of IL-7R Subsets that express it generally require it, including progenitors of T and B cells, naïve and memory T cells. (Pandrau-Garcia D et al, 1994, Blood, 83, 3613-9 Mazzucchelli R et al, Nat. Review Immunol., 2007,7, 144-54) |
) Anti-IL7R antibody (Alexa-fluor 546) |
|
STJ170021 |
St John's Laboratory |
100 µg |
EUR 393 |
|
Description: The IL7-R consists of 2 chains, IL-7R known as CD127 and common cytokine receptor chain known as CD132. A 75 to 80kDa human IL-7 receptor has been cloned that belongs to hematopoietic cytokinereceptor super family. R34-34, raised against human leukemic pre-B cells, recognized a molecule expressed on normal B cell precursors but not on mature B cells. This antibody specifically reverted IL-7 mediated growth inhibition of leukemic BCP (normal B cells precursors) and mature T cells. IL-7R expression is dramatically influenced by cytokines and antigens. This IL-7R displays both high and low affinity for its ligand (IL-7). Inhibitory and proliferative effects of IL-7 can be mediated through the same receptor on various lineages. CD4+ memory T cells express high level of IL-7R Subsets that express it generally require it, including progenitors of T and B cells, naïve and memory T cells. (Pandrau-Garcia D et al, 1994, Blood, 83, 3613-9 Mazzucchelli R et al, Nat. Review Immunol., 2007,7, 144-54) |
) Anti-IL7R antibody (Alexa-fluor 647) |
|
STJ170022 |
St John's Laboratory |
100 µg |
EUR 393 |
|
Description: The IL7-R consists of 2 chains, IL-7R known as CD127 and common cytokine receptor chain known as CD132. A 75 to 80kDa human IL-7 receptor has been cloned that belongs to hematopoietic cytokinereceptor super family. R34-34, raised against human leukemic pre-B cells, recognized a molecule expressed on normal B cell precursors but not on mature B cells. This antibody specifically reverted IL-7 mediated growth inhibition of leukemic BCP (normal B cells precursors) and mature T cells. IL-7R expression is dramatically influenced by cytokines and antigens. This IL-7R displays both high and low affinity for its ligand (IL-7). Inhibitory and proliferative effects of IL-7 can be mediated through the same receptor on various lineages. CD4+ memory T cells express high level of IL-7R Subsets that express it generally require it, including progenitors of T and B cells, naïve and memory T cells. (Pandrau-Garcia D et al, 1994, Blood, 83, 3613-9 Mazzucchelli R et al, Nat. Review Immunol., 2007,7, 144-54) |
 Endoglin/CD105 Alexa Fluor |
|
FC15024 |
Neuromics |
100 Tests |
EUR 448 |
) DyLight®594 Conjugated Goat Anti-mouse IgG (H+L) |
|
BA1141-0.5 |
BosterBio |
0.5ml |
EUR 202 |
|
DyLight®594 Conjugated Goat Anti-mouse IgG (H+L) |
|
BA1141-1 |
BosterBio |
1ml |
EUR 334 |
 Anti-Hu CD16 Alexa Fluor® 488 |
|
A4-646-T100 |
ExBio |
100 tests |
EUR 269 |
) EGFR antibody (Alexa Fluor 488) |
|
61R-E109BAF |
Fitzgerald |
125 ug |
EUR 706 |
|
Description: Mouse monoclonal EGFR antibody (Alexa Fluor 488) |
) SAM FCM (Alexa Fluor 647) |
|
abx098902-100tests |
Abbexa |
100 tests |
EUR 1233 |
- Shipped within 5-10 working days.
|
) SAM FCM (Alexa Fluor 488) |
|
abx098904-60tests |
Abbexa |
60 tests |
EUR 1358 |
- Shipped within 5-10 working days.
|
-Alexa 488 Fluor conjugate (adsorbed with human IgG)) Rabbit Anti-Rat IgG (H+L)-Alexa 488 Fluor conjugate (adsorbed with human IgG) |
|
50336 |
Alpha Diagnostics |
0.5 ml |
EUR 225 |
) DyLight®594 Conjugated Goat Anti-rabbit IgG (H+L) |
|
BA1142-0.5 |
BosterBio |
0.5ml |
EUR 202 |
|
DyLight®594 Conjugated Goat Anti-rabbit IgG (H+L) |
|
BA1142-1 |
BosterBio |
1ml |
EUR 334 |
) iFluor™ 594 goat anti-mouse IgG (H+L) |
|
16468 |
AAT Bioquest |
200 ug |
EUR 115 |
- R-phrase: R20, R21, R22
- H-Phrase: H303, H313, H333
- Symbol for dangerous compounds: Xn
- UNSPEC Code: 12171501
|
|
iFluor™ 594 goat anti-mouse IgG (H+L) |
|
16741 |
AAT Bioquest |
1 mg |
EUR 176 |
- R-phrase: R20, R21, R22
- H-Phrase: H303, H313, H333
- Symbol for dangerous compounds: Xn
- UNSPEC Code: 12171501
|
 Antibody (DyLight 594)) Goat Anti-Mouse IgG (H+L) Antibody (DyLight 594) |
|
20-abx007449 |
Abbexa |
|
|
- Shipped within 5-10 working days.
|
 (Alexa Fluor 647)) Donkey anti Chicken IgY (H + L) (Alexa Fluor 647) |
|
43R-ID060AF |
Fitzgerald |
300 ug |
EUR 425 |
|
Description: Donkey anti Chicken IgY (H + L) (Fab'2) (Alexa Fluor 647) |
 Anti-Hu CD72 Alexa Fluor® 488 |
|
A4-310-T100 |
ExBio |
100 tests |
EUR 269 |
 Anti-Bov CD9 Alexa Fluor® 488 |
|
A4-354-C100 |
ExBio |
0.1 mg |
EUR 269 |
 Anti-Hu CD30 Alexa Fluor® 700 |
|
A7-455-T100 |
ExBio |
100 tests |
EUR 269 |
 Anti-Hu CD94 Alexa Fluor® 700 |
|
A7-727-T100 |
ExBio |
100 tests |
EUR 269 |
 Anti-Hu CD56 Alexa Fluor® 700 |
|
A7-789-T100 |
ExBio |
100 tests |
EUR 269 |
 Alpha Fluor™ 594 C5 Maleimide |
|
1891 |
AAT Bioquest |
1 mg |
EUR 219 |
- R-phrase: R20, R21, R22
- H-Phrase: H303, H313, H333
- Symbol for dangerous compounds: Xn
- UNSPEC Code: 12171501
|
 conjugate) Streptavidin-Alexa594 (Alexas fluor 594) conjugate |
|
SV-A594-100 |
Alpha Diagnostics |
100 tests |
EUR 225 |
) Goat anti-Mouse IgG SecondaryAntibody (peroxidase conjugated) |
|
E0L3032-1 |
EnoGene |
500ul |
EUR 128 |
) iFluor™ 594 goat anti-rabbit IgG (H+L) |
|
16628 |
AAT Bioquest |
200 ug |
EUR 115 |
- R-phrase: R20, R21, R22
- H-Phrase: H303, H313, H333
- Symbol for dangerous compounds: Xn
- UNSPEC Code: 12171501
|
|
iFluor™ 594 goat anti-rabbit IgG (H+L) |
|
16806 |
AAT Bioquest |
1 mg |
EUR 176 |
- R-phrase: R20, R21, R22
- H-Phrase: H303, H313, H333
- Symbol for dangerous compounds: Xn
- UNSPEC Code: 12171501
|
 Antibody (DyLight 594)) Rabbit Anti-Goat IgG (H+L) Antibody (DyLight 594) |
|
20-abx007407 |
Abbexa |
|
|
- Shipped within 5-10 working days.
|
 Antibody (DyLight 594)) Goat Anti-Rat IgG (H+L) Antibody (DyLight 594) |
|
20-abx007419 |
Abbexa |
|
|
- Shipped within 5-10 working days.
|
 Antibody (DyLight 594)) Goat Anti-Rabbit IgG (H+L) Antibody (DyLight 594) |
|
20-abx007433 |
Abbexa |
|
|
- Shipped within 5-10 working days.
|
 Alpha Fluor™ 532 acid [equivalent to Alexa Fluor™ 532 acid] |
|
1795 |
AAT Bioquest |
10 mg |
EUR 393 |
- R-phrase: R20, R21, R22
- H-Phrase: H303, H313, H333
- Symbol for dangerous compounds: Xn
- UNSPEC Code: 12171501
|
 *Cross Adsorbed*) iFluor™ 594 goat anti-mouse IgG (H+L) *Cross Adsorbed* |
|
16548 |
AAT Bioquest |
200 ug |
EUR 132 |
- R-phrase: R20, R21, R22
- H-Phrase: H303, H313, H333
- Symbol for dangerous compounds: Xn
- UNSPEC Code: 12171501
|
|
iFluor™ 594 goat anti-mouse IgG (H+L) *Cross Adsorbed* |
|
16780 |
AAT Bioquest |
1 mg |
EUR 219 |
- R-phrase: R20, R21, R22
- H-Phrase: H303, H313, H333
- Symbol for dangerous compounds: Xn
- UNSPEC Code: 12171501
|
 Goat anti Mouse IgG |
|
20-B9015G000-S0 |
Fitzgerald |
10 ml |
EUR 133 |
|
Description: Goat anti Mouse IgG antibody |
|
Goat anti Mouse IgG |
|
20-S8301G000-V0 |
Fitzgerald |
10 ml |
EUR 133 |
|
Description: Goat anti Mouse IgG antibody |
|
Goat anti Mouse IgG |
|
41-GM25 |
Fitzgerald |
20 mg |
EUR 184 |
|
Description: Goat anti Mouse IgG secondary antibody |
|
Goat anti Mouse IgG |
|
41R-1058 |
Fitzgerald |
2 mg |
EUR 149 |
|
Description: Goat anti Mouse IgG secondary antibody |
|
Goat anti Mouse IgG |
|
40-GM25S |
Fitzgerald |
100 ml |
EUR 133 |
|
Description: Goat anti Mouse IgG secondary antibody |
|
Goat anti Mouse IgG |
|
40-S8301G000-S4 |
Fitzgerald |
10 ml |
EUR 133 |
|
Description: Goat anti Mouse IgG secondary antibody |
 Goat Anti Mouse IgG |
|
E61I00501 |
EnoGene |
100ug |
EUR 343 |
 Goat Anti-mouse IgG |
|
STJ15100178 |
St John's Laboratory |
250 µg |
EUR 283 |
|
Description: Biotinylated goat anti-mouse IgG enables detection of mouse IgG in enzyme immunoassays such as indirect ELISA. |
 Alexa Fluor<sup>®</sup> 488) Anti-Hu CD3 zeta (pY153) Alexa Fluor® 488 |
|
A4-686-C100 |
ExBio |
0.1 mg |
EUR 269 |
 Alexa Fluor<sup>®</sup> 488) Anti-Hu CD3 zeta (pY72) Alexa Fluor® 488 |
|
A4-712-C100 |
ExBio |
0.1 mg |
EUR 269 |
 Alexa Fluor<sup>®</sup> 488) Anti-Hu CD3 zeta (pY142) Alexa Fluor® 488 |
|
A4-730-C100 |
ExBio |
0.1 mg |
EUR 269 |
 Alexa Fluor<sup>®</sup> 488) Anti-Hu CD3 zeta (pY111) Alexa Fluor® 488 |
|
A4-737-C100 |
ExBio |
0.1 mg |
EUR 269 |
 Alexa Fluor<sup>®</sup> 647) Anti-Hu CD3 zeta (pY153) Alexa Fluor® 647 |
|
A6-686-C100 |
ExBio |
0.1 mg |
EUR 269 |
 Alexa Fluor<sup>®</sup> 647) Anti-Hu CD3 zeta (pY72) Alexa Fluor® 647 |
|
A6-712-C100 |
ExBio |
0.1 mg |
EUR 269 |
 Alexa Fluor<sup>®</sup> 647) Anti-Hu CD3 zeta (pY142) Alexa Fluor® 647 |
|
A6-730-C100 |
ExBio |
0.1 mg |
EUR 269 |
 Alexa Fluor<sup>®</sup> 647) Anti-Hu CD3 zeta (pY111) Alexa Fluor® 647 |
|
A6-737-C100 |
ExBio |
0.1 mg |
EUR 269 |
 Polyclonal Goat anti-GST α-form |
|
GST-ANTI-1 |
Detroit R&D |
50 uL |
EUR 280 |
 Polyclonal Goat anti-GST μ-form |
|
GST-ANTI-2 |
Detroit R&D |
50 uL |
EUR 280 |
 Polyclonal Goat anti-GST p-form |
|
GST-ANTI-3 |
Detroit R&D |
50 uL |
EUR 280 |
 (Agarose Conjugated)) Goat anti Mouse IgG (H + L) (Agarose Conjugated) |
|
43R-IG044AS |
Fitzgerald |
20 mg |
EUR 488 |
|
Description: Goat anti Mouse IgG (H + L) secondary antibody (Agarose Conjugated) |
 HRP-conjugated Goat Anti-Mouse IgG Heavy Chain |
|
AS064 |
Abclonal |
100 ul |
EUR 152 |
， Biotin Conjugated) Goat anti-Mouse IgG(H+L)， Biotin Conjugated |
|
E16SPB101-100 |
EnoGene |
100Tests |
EUR 343 |
|
Goat anti-Mouse IgG(H+L)， Biotin Conjugated |
|
E16SPB101-1000 |
EnoGene |
1000Tests |
EUR 245 |
|
Goat anti-Mouse IgG(H+L)， Biotin Conjugated |
|
E16SPB101-500 |
EnoGene |
500Tests |
EUR 167 |
， FITC Conjugated) Goat anti-Mouse IgG(H+L)， FITC Conjugated |
|
E16SPF101-050 |
EnoGene |
50Tests |
EUR 239 |
|
Goat anti-Mouse IgG(H+L)， FITC Conjugated |
|
E16SPF101-100 |
EnoGene |
100Tests |
EUR 343 |
|
Goat anti-Mouse IgG(H+L)， FITC Conjugated |
|
E16SPF101-100U |
EnoGene |
100μg |
EUR 239 |
|
Goat anti-Mouse IgG(H+L)， FITC Conjugated |
|
E16SPF101-500U |
EnoGene |
500μg |
EUR 343 |
 ,HRPO Conjugated) Goat anti-Mouse IgG(H+L) ,HRPO Conjugated |
|
E16SPH101-100 |
EnoGene |
100μl |
EUR 239 |
|
Goat anti-Mouse IgG(H+L) ,HRPO Conjugated |
|
E16SPH101-1000 |
EnoGene |
1000μl |
EUR 434 |
|
Goat anti-Mouse IgG(H+L) ,HRPO Conjugated |
|
E16SPH101-500 |
EnoGene |
500μl |
EUR 343 |
， PE Conjugated) Goat anti-Mouse IgG(H+L)， PE Conjugated |
|
E16SPP101-020 |
EnoGene |
20Tests |
EUR 239 |
|
Goat anti-Mouse IgG(H+L)， PE Conjugated |
|
E16SPP101-050 |
EnoGene |
50Tests |
EUR 239 |
|
Goat anti-Mouse IgG(H+L)， PE Conjugated |
|
E16SPP101-100U |
EnoGene |
100ug |
EUR 239 |
|
Goat anti-Mouse IgG(H+L)， PE Conjugated |
|
E16SPP101-500U |
EnoGene |
500ug |
EUR 343 |
 Goat Anti-Mouse IgG Secondary Antibody AF790 Conjugated |
|
L30310 |
SAB |
0.5 ml |
EUR 126 |
 Goat Anti-Mouse IgG Secondary Antibody Cy3 Conjugated |
|
L30311 |
SAB |
1.0 ml |
EUR 112 |
Low-temperature (70°C inlet temperature) drying with an electrostatic cost (5kV) led to higher protein bodily stability as in contrast with the samples spray-dried at the excessive temperature (130°C inlet temperature) with out cost. This research exhibits that electrostatic spray drying can produce strong monoclonal antibody formulation at decrease inlet temperature than conventional spray drying with higher bodily stability.
